ÂÜÀòÂÒÂ×

Mr. Krick was named Vice President and Chief Accounting Officer in June 2022, in this role, he is responsible for leading all finance and accounting activities. He joined Optinose in November 2021 as Vice President, Controller. Prior to joining Optinose, Mr. Krick served as the Corporate Controller of Verrica Pharmaceuticals, a publicly held dermatology company, where he was responsible for all financial planning & analysis, accounting, and financial reporting activities. Prior to joining Verrica, Mr. Krick served as Executive Director, Financial Planning & Analysis at Strongbridge Biopharma, a publicly held commercial stage rare disease company. While at Strongbridge, he was responsible for the company’s short- and long-term financial planning, finance partnering activities, and transaction support for financing and business development activities.

Earlier in is career, Mr. Krick held a number of positions of increasing responsibility at GlaxoSmithKline and Endo Pharmaceuticals, including finance roles supporting commercial and research and development organizations, as well as corporate roles in technical accounting and financial reporting. Mr. Krick began his career at Ernst & Young LLP, where he served clients in the biotechnology and pharmaceutical industries.

Mr. Krick holds a Bachelor of Science in accounting from Albright College and is a Certified Public Accountant (inactive status).